Company ProQR Therapeutics N.V.

Equities

PRQR

NL0010872495

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per region

Ratings for ProQR Therapeutics N.V.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 03:43:40 2024-04-25 pm EDT			5-day change	1st Jan Change
1.965 ^USD	-2.24%		+6.71%	+0.24%

Mar. 14	Chardan Raises ProQR Therapeutics' PT to $2.50 From $2, Says ADAR-Based Therapeutics to Enter Clinical Development, Keeps Buy Rating	MT
Mar. 13	ProQR Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leberâs congenital amaurosis (LCA).

USD in Million	2022	Weight	2023	Weight	Delta
RNA Based Therapeutics 100.0 %	4	100.0 %	7	100.0 %	+65.99%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	4	100.0 %	7	100.0 %	+65.99%

Managers	Title	Age	Since
Daniel de Boer CEO	Chief Executive Officer	41	12-02-20
Gerard J. Platenburg FOU	Founder	60	12-02-20
Jurriaan Dekkers DFI	Director of Finance/CFO	-	22-09-30
Sheila Sponselee COO	Chief Operating Officer	-	20-03-31
Sarah Kiely IRC	Investor Relations Contact	-	19-09-30
Andrew Morris PRN	Corporate Officer/Principal	-	18-12-31
René Beukema LAW	General Counsel	60	13-08-31

Members of the board	Title	Age	Since
Domenico Valerio FOU	Founder	67	12-02-20
Gerard J. Platenburg FOU	Founder	60	12-02-20
Alison Lawton BRD	Director/Board Member	62	14-09-16
Bart Filius BRD	Director/Board Member	53	19-05-20
James Shannon BRD	Director/Board Member	67	16-06-20
Theresa Heggie COO	Chief Operating Officer	63	19-06-30
Begoña Carreño BRD	Director/Board Member	52	22-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	84,248,384	66,003,992 ( 78.34 %)	0	78.34 %

Name	Equities	%	Valuation
ELI LILLY AND COMPANY 16.55 %	13,371,562	16.55 %	31 M $
Van Herk Investments BV 10.11 %	8,170,254	10.11 %	19 M $
Privium Fund Management BV 6.613 %	5,344,446	6.613 %	12 M $
Aescap Venture Management BV 5.897 %	4,765,659	5.897 %	11 M $
Adage Capital Partners GP LLC 4.486 %	3,625,467	4.486 %	8 M $
EcoR1 Capital, LLC 3.687 %	2,980,016	3.687 %	7 M $
M28 Capital Management LP 2.364 %	1,910,600	2.364 %	4 M $
DAFNA Capital Management LLC 1.164 %	940,582	1.164 %	2 M $
De Grote Voskuil Capital BV 0.9156 %	740,000	0.9156 %	2 M $
Domenico Valerio 0.8979 %	725,692	0.8979 %	2 M $

ProQR Therapeutics NV

Zernikedreef 9

2333 CK, Leiden

+31 88 166 7000

http://www.proqr-tx.com

Name	Category and Sector
Amylon Therapeutics BV Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands.	Pharmaceuticals: Major

Name

Category and Sector

Pharmaceuticals: Major

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.01 USD

Average target price

4.1 USD

Spread / Average Target

+103.98%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PROQR THERAPEUTICS N.V.	+1.52%	164M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs